BIOCORP
16.9.2021 07:32:13 CEST | Business Wire | Press release
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and Merck, a leading science and technology company, today announce an agreement for the development and supply of a specific version of Mallya device to monitor treatment adherence in the field of HGH.
Manufactured in Clermont-Ferrand (France), Mallya is a Bluetooth enabled clip-on device for pen injectors that collects dose and time of each injection and transfers information in real time to a companion software. Mallya is the first in its category to receive the CE-mark (medical device) and commercial versions for insulin pen injectors are already available and distributed in Europe and other geographies.
Healthcare companies BIOCORP and Merck will develop a specific version for applications in the field of Human Growth Hormone. The device will help patients (children and teenagers) automatically keep track of their HGH daily injection and monitor adherence with their treatment plan.
Following the completion of different milestones, Merck will pay around €3 million for the development of the specific solution. After the development phase, BIOCORP will manufacture the commercial units on behalf of Merck, which will generate additional revenues.
Once the development Is completed, the objective Is to market the product on a Global scale
“We are very excited about this new agreement concerning Mallya. Not only are we collaborating with a new major player in the pharmaceutical industry, but we are also expanding the scope of Mallya. After the monitoring of patients living with diabetes, our medical device proves its usefulness and safety for children and teenagers undergoing growth hormone injection, ” said Éric Dessertenne, CEO of BIOCORP.
ABOUT BIOCORP Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR). For more information, please visit www.biocorpsys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915006165/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CEO Pay Tops $18 Million as Turnover Drives Six-Year High in Sign-On Bonuses, According to Diligent29.9.2026 15:00:00 CEST | Press release
New Diligent Market Intelligence report finds succession costs rising as boards compete for scarce leadership talent and compensation committees face sharper investor scrutiny Median granted CEO pay at S&P 500 companies rose by more than 8% in 2025 to reach $18.2 million, while cash sign-on bonuses for incoming CEOs hit a six-year high, according to the Executive Compensation in 2026 report from Diligent Market Intelligence. The findings point to a more consequential compensation environment for boards: leadership talent is in shorter supply, CEO transitions are costly, and investors continue to scrutinize how pay decisions connect to performance and long-term value. The Russell 3000 also saw remuneration packages grow larger, with median granted CEO pay climbing over 2% to $7.4 million. “This level of growth has been fueled by performance-based equity and stock awards while both indices have been delivering strong total shareholder returns,” said Josh Black, Editor-in-Chief of Diligen
Momentum Grows for Miro MCP as Users Embrace the Canvas for AI Collaboration29.9.2026 15:00:00 CEST | Press release
Calls to Miro’s MCP server surge past 16 million; MCP jumps the developer niche with individuals in non-engineering roles now among the majority embracing the technology Miro®, the collaboration and context layer for the AI era, has reported more than 16 million calls to its MCP server since its launch in February 2026, with usage more than doubling since May. In September alone, MCP calls are on track to reach 6 million*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929837812/en/ Miro's MCP server is a Model Context Protocol integration letting AI tools connect to Miro boards—creating diagrams, tables, and canvas content, and reading existing board data programmatically. Teams increasingly rely on AI to accelerate work—from discovery and planning to design and code. Yet most AI interactions happen in chat windows or static outputs that exist separately from the team's actual workspace. Miro's MCP server changes this by
NTT DATA Launches ‘Intact, intelligent action.’ to Protect Fragile Places and Advance Sustainability Commitments29.9.2026 15:00:00 CEST | Press release
Global initiative will combine awareness, technology and stewardship to support fragile places around the world. Program will help translate sustainability commitments into practical actions. In the initiative’s first chapter, NTT DATA employees will join Antarctic expedition led by Robert Swan, OBE, on the 40th anniversary of his first South Pole expedition. NTT DATA, a global leader in AI, digital business and technology services, today announced “Intact, intelligent action.” This global initiative is designed to help people and organizations translate sustainability commitments into meaningful action. The effort combines awareness, technology and stewardship in support of some of the world’s most treasured yet fragile places. Antarctica will be the first chapter. From November 25 to December 2, 2026, a dozen NTT DATA employees will join polar explorer Robert Swan and his 2041 Leadership on the Edge expedition aboard the Magellan Explorer. With the Antarctic Peninsula and nearby isla
I-SEC Optimizes Airport Security Workforce Planning with Gurobi and Syntro29.9.2026 15:00:00 CEST | Press release
I-SEC navigates growing complexity with optimization—improving efficiency and ensuring regulatory compliance while keeping employee needs in mind. Gurobi Optimization, LLC, the leader in decision intelligence technology, and its partner Syntro, a provider of workforce scheduling solutions, are helping organizations like I-SEC, an international provider of airport security services, make better operational decisions in increasingly complex and highly regulated operating environments. As organizations face growing pressure to balance labor costs, regulatory requirements, service levels, and employee needs, many are turning to mathematical optimization to improve operational decision making. Airport security workforce planning is particularly complex, requiring organizations to align staffing levels with changing passenger volumes while adhering to strict regulations, accounting for required breaks and certifications, and ensuring coverage across multiple locations and checkpoints. Workin
ACIC Equipment President Patrice Pelletier to Attend CPHI Milan 202629.9.2026 15:00:00 CEST | Press release
ACIC Equipment USA will join ACIC Pharmaceuticals at CPHI Milan 2026, bringing together ACIC's pharmaceutical expertise and global network of technology partners to showcase an integrated approach to pharmaceutical development, manufacturing and commercialization. From October 6–8, 2026, visitors to Stand 7G106 can meet both teams and discover how ACIC connects pharmaceutical expertise, advanced manufacturing technologies and specialized engineering to help customers move projects from molecule to market. At the heart of ACIC Equipment's offering is a carefully selected network of leading technology partners, combined with ACIC's integration expertise and North American commercial and technical support. Together, they give pharmaceutical manufacturers access to specialized technologies across radiopharmaceutical production, aseptic processing, sterilization and contamination control, formulation and pure-fluid systems, filling and inspection, freeze drying, cleanrooms, packaging, vacuu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom